Page 104 - Read Online

Page 18 of 18 Kozarov et al. Vessel Plus 2020;4:10 I http://dx.doi.org/10.20517/2574-1209.2019.31

peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis 2008;196:937-42.
152. Vainas T, Stassen FR, Schurink GW, Tordoir JH, Welten RJ, et al. Secondary prevention of atherosclerosis through chlamydia
pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease. Eur J Vasc Endovasc
Surg 2005;29:403-11.
153. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, et al. Rationale and design of the Cardiovascular Inflammation
Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207.e15.
154. Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin
Climatol Assoc 2013;124:174-90.
155. Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep 2013;15:295.
156. Moreira DM, Lueneberg ME, da Silva RL, Fattah T, Mascia Gottschall CA. Rationale and design of the TETHYS trial: the effects of
methotrexate therapy on myocardial infarction with ST-segment elevation. Cardiology 2013;126:167-70.
157. O’Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, et al. Effect of darapladib on major coronary events after an acute
coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006-15.
158. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the
WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. J Infect Dis
2000;181:S572-8.
159. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for
future research. Circulation 1997;96:4095-103.
160. Amar S, Engelke M. Periodontal innate immune mechanisms relevant to atherosclerosis. Mol Oral Microbiol 2015;30:171-85.
161. Kesavalu L, Lucas AR, Verma RK, Liu L, Dai E, et al. Increased atherogenesis during Streptococcus mutans infection in ApoE-null
mice. J Dent Res 2012;91:255-60.
162. Kozarov E, Huber K, Wojta J. Infection-associated biomarkers of inflammation in atherosclerosis. Curr Pharm Des 2015;21:1776-82.
163. Kramer CD, Simas AM, He X, Ingalls RR, Weinberg EO, et al. Distinct roles for dietary lipids and Porphyromonas gingivalis
infection on atherosclerosis progression and the gut microbiota. Anaerobe 2017;45:19-30.
164. Anderson JL. Infection, antibiotics, and atherothrombosis--end of the road or new beginnings? N Engl J Med 2005;352:1706-9.
165. Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, et al. Chlamydia pneumoniae infection in circulating human monocytes is
refractory to antibiotic treatment. Circulation 2001;103:351-6.
166. Deshpande RG, Khan M, Genco CA. Invasion strategies of the oral pathogen porphyromonas gingivalis: implications for
cardiovascular disease. Invasion Metastasis 1998-1999;18:57-69.
167. Dorn BR, Dunn WA Jr, Progulske-Fox A. Invasion of human coronary artery cells by periodontal pathogens. Infect Immun
1999;67:5792-8.
168. Lamont RJ, Chan A, Belton CM, Izutsu KT, Vasel D, et al. Porphyromonas gingivalis invasion of gingival epithelial cells. Infect
Immun 1995;63:3878-85.
169. Progulske-Fox A, Kozarov E, Dorn B, Dunn W Jr, Burks J, et al. Porphyromonas gingivalis virulence factors and invasion of cells of
the cardiovascular system. J Periodontal Res 1999;34:393-9.
170. Wunsch CM, Lewis JP. Porphyromonas gingivalis as a Model Organism for Assessing Interaction of Anaerobic Bacteria with Host
Cells. J Vis Exp 2015;e53408.
171. Griffen AL, Becker MR, Lyons SR, Moeschberger ML, Leys EJ. Prevalence of Porphyromonas gingivalis and periodontal health
status. J Clin Microbiol 1998;36:3239-42.
172. Rudney JD, Chen R. The vital status of human buccal epithelial cells and the bacteria associated with them. Arch Oral Biol
2006;51:291-8.
173. Donley TG. Time to put periodontal disease on the list of chronic inflammatory diseases contributing to premature atherosclerosis.
CMAJ 2019;191:E52.
174. Demmer RT, Desvarieux M. Periodontal infections and cardiovascular disease: the heart of the matter. J Am Dent Assoc 2006;137:14S-38.